Schertz 1996.

Methods	A retrospective study examining predictors of weight loss in children with ADHD treated with methylphenidate or dextroamphetamine sulfate
Participants	Number of participants screened: not stated Number of participants included: 60 (total) Number of participants included in methylphenidate group: 32 Number followed up: 60 Number of withdrawals: 0 Diagnosis of ADHD: DSM‐III‐R (subtype: not stated) Age: mean 7.5 years old (range: 3.6‐15.5) IQ: no mental retardation Sex: 29 males, 3 females Methylphenidate‐naïve: 0 Ethnicity: white 77%, African American 10%, Asian: 3%, Hispanic: 10% Country: USA Comorbidity: not stated Comedication: not stated Sociodemographics: not stated Inclusion criteria: DSM‐III‐R diagnosis of ADHD ≥ 5 months treatment with methylphenidate in the Developmental and Behavioral Pediatrics of the Schneider Children's Hospital Exclusion criteria: Prior trial of methylphenidate stimulant medication Concurrently taking a medication that can affect weight (e.g. clonidine) Having a major developmental disability (e.g. mental retardation, cerebral palsy or autism) If complete information was not available in the chart
Interventions	Methylphenidate type: not stated Mean methylphenidate dosage: 25.5 mg or 1 mg/kg/day Administration schedule: not stated Duration of intervention: mean duration 11.2 months (range 6‐20 months) Treatment compliance: not assessed
Outcomes	Weight and body mass index (BMI) were the 2 measures of adiposity used. Weight was expressed in terms of z scores derived from US normative data
Notes	Sample calculation: no Ethics approval: not stated Funding: not stated Vested interests/authors' affiliations: not stated Key conclusions of the study authors: pretreatment weight, adjusted for age, gender and height is a significant predictor of weight loss in children with ADHD treated with either methylphenidate or dextroamphetamine sulphate. In contrast, pretreatment age, duration of treatment, and weight‐adjusted dose were not found to be significant predictors Exclusion of methylphenidate non‐responders/children who have previously experienced adverse events on methylphenidate: not stated Supplemental information regarding height and weight for the methylphenidate group requested from the authors by email correspondence in January 2014. No reply